Evidence map›Paper›PMID 36768310›Full record

ArticleInternational journal of molecular sciences2023

Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen

Parish P Sedghizadeh, Philip Cherian, Sahar Roshandel, Natalia Tjokro, Casey Chen, Adam F Junka, Eric Hu, Jeffrey Neighbors, Jacek Pawlak, R Graham G Russell and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Bisphosphonate-Conjugated Sitafloxacin for Treatment ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Parish P SedghizadehDivision of Periodontology, Diagnostic Sciences and Dental Hygiene, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA 90007, USA.ORCID 0000-0003-4190-0497
Philip CherianBioVinc LLC, Pasadena, CA 91107, USA.ORCID 0000-0002-1070-6483
Sahar RoshandelBioVinc LLC, Pasadena, CA 91107, USA.
Natalia TjokroDivision of Periodontology, Diagnostic Sciences and Dental Hygiene, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA 90007, USA.
Casey ChenDivision of Periodontology, Diagnostic Sciences and Dental Hygiene, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA 90007, USA.
Adam F JunkaDepartment of Pharmaceutical Microbiology and Parasitology, Medical University of Wroclaw, 50-367 Wroclaw, Poland.ORCID 0000-0002-7559-8903
Eric HuBioVinc LLC, Pasadena, CA 91107, USA.
Jeffrey NeighborsBioVinc LLC, Pasadena, CA 91107, USA.
Jacek PawlakMedical Department, Lazarski University, 02-662 Warsaw, Poland.
R Graham G RussellThe Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX1 2JD, UK.
Charles E McKennaDepartment of Chemistry, University of Southern California, Los Angeles, CA 90007, USA.
Frank H EbetinoBioVinc LLC, Pasadena, CA 91107, USA.ORCID 0000-0002-9133-1360
Shuting SunBioVinc LLC, Pasadena, CA 91107, USA.
Esmat SodagarDivision of Periodontology, Diagnostic Sciences and Dental Hygiene, Infection and Immunity Laboratory, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA 90007, USA.
BioVinc (United States) · USUniversity of Southern California · USNuffield Orthopaedic Centre · GBPennsylvania State University · USUczelnia Łazarskiego · PLUniversity of Wrocław · PL

Funding

DOCTORAL AND POST-DOCTORAL TRAINING IN CRANIOFACIAL BIOLOGYT90DE021982 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PAINE, MICHAEL LANSDELL · 2011 to 2025
$6.2M
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatmentR42DE025789 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H., SEDGHIZADEH, PARISH PAYMON · 2017 to 2018
$1.5M
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatmentR41DE025789 · NIDCR · BIOVINC, LLC · PI EBETINO, FRANK H., SEDGHIZADEH, PARISH PAYMON · 2016 to 2016
$150k
NIDCR NIH HHS R41 DE025789NIDCR NIH HHS R42 DE025789NIDCR NIH HHS R42DE025789NIDCR NIH HHS T90 DE021982NIH HHS R41DE025789
6 · The paper itself

Abstract

Osteomyelitis is a limb- and life-threatening orthopedic infection predominantly caused by

Indexed as

OsteomyelitisStaphylococcal InfectionsAnti-Bacterial AgentsBiofilmsCiprofloxacinDiphosphonatesDurapatiteElectric ImpedanceEtidronic AcidHumansMicrobial Sensitivity TestsMoxifloxacinStaphylococcus aureusAnti-Bacterial AgentsCiprofloxacinDiphosphonatesDurapatiteEtidronic AcidMoxifloxacinantibioticbiofilmbisphosphonatebone targetingconjugatefluoroquinoloneimpedanceStaphylococcus

Identifiers

PMID36768310
PMCPMC9915994
OpenAlexW4317508559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.